<DOC>
	<DOC>NCT00540150</DOC>
	<brief_summary>We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy. Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22 patients for 6 weeks with the shortened scheme.</brief_summary>
	<brief_title>Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy</brief_title>
	<detailed_description>see above</detailed_description>
	<criteria>informed consent of patient and/or parents age &gt;6 and &lt;18 years bronchial asthma I째 or II째 allergy on house dustmite age &lt;6 and &gt;18 years vital capacity &lt;80% or FEV1 &lt;70% pregnancy inhalative or systemic steroid use bronchial asthma III째 or IV째 heavy exacerbation during the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Mite</keyword>
	<keyword>Asthma</keyword>
	<keyword>bronchial provocation</keyword>
	<keyword>SIT</keyword>
	<keyword>specific immunotherapy</keyword>
</DOC>